Supplementary Materials

The PDF file includes:

  • Supplementary Materials and Methods
  • Fig. S1. Efficient HAdv-C5 virus sequestration in liver macrophages requires natural IgM antibodies and scavenger receptor CD36.
  • Fig. S1. GVHD assessment in the BALB/c +T ➔C57BL/6 mouse model.
  • Fig. S2. GVHD assessment in the B10.D2 +SC ➔BALB/c mouse model.
  • Fig. S3. T cell phenotype in the B10.D2 +SC ➔BALB/c and GVHD outcome with CD4+ T cell transplant.
  • Fig. S4. Association between baseline ST2 and overall survival after allo-HSCT.
  • Fig. S5. GVHD outcomes in the C3H.SW (+CD8 or +T) ➔C57BL/6 mouse model.
  • Fig. S6. Activation of DCs in the B10.D2 (+SC or +CD4 or +CD8) ➔BALB/c mouse model.
  • Fig. S7. Gut microbiota composition of control and DIO BALB/c mice on a high-fat diet for 1 or 4 months.
  • Fig. S8. Comparison of gut microbiota profiles between control and DIO mice, and between lean and obese human samples.
  • Fig. S9. Donor cell engraftment in control, DIO, and antibiotic-treated DIO BALB/c mice after allo-HSCT.
  • Fig. S10. Distinct baseline gut microbiota profiles of control, DIO, and antibiotic-treated DIO BALB/c and C57BL/6 mice.
  • Fig. S11. DC activation and sclerodermatous cGVHD in control, DIO, and antibiotic-treated DIO BALB/c mice after allo-HSCT.
  • Table S1. Characteristics of patient cohorts at the University of Minnesota and Mt. Sinai’s Tisch Cancer Institute.
  • Table S2. Characteristics of patients undergoing fecal microbiota analysis at the University of Minnesota.

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Data file S1 (Microsoft Excel format). Individual-level data for all figures.